Phytochemicals as Potential Anti-Alzheimer s Agents- An In-Silico Evidence

Research Article

J Dis Markers. 2022; 7(1): 1047.

Phytochemicals as Potential Anti-Alzheimer’s Agents- An In-Silico Evidence

Pandey D, Pal T and Sharma A*

Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, Raebareli, India

*Corresponding author: Abha Sharma, Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, Raebareli, India

Received: August 11, 2022; Accepted: September 09, 2022; Published: September 16, 2022

Abstract

Alzheimer’s Disease is a prominent neurodegenerative disorder affecting the age group 60 and above. Cholinergic hypothesis, amyloid β cascade, oxidative stress is some of the known etiologies of marked importance to name a few. We have undertaken a computational analysis where fifteen phytochemicals were selected. These natural molecules were studied and analysed against acetylcholinesterase, butyrlcholinesterase, BACE and amyloid β monomer and protofibril. The binding affinities of Genistein, Huperzine A, kaempferol, Methyl quercetin, Paclitaxel and Withinolide A against AChE and BuChE enzymes were found to be -7.7 to -8.6 Kcal/mol, respectively. Various phytochemicals like Genistein, kaempferol, Piceatannol, Ginkgolide B, Methyl quercetin and Withinolide A were found to bind the BACE-1 enzyme with the binding affinities of -6.7 to -7.9 Kcal/mol. All the phytochemicals experienced efficient binding towards Aβ monomer and Aβ protofibril. Withinolide A was found to bind all the PDB’s efficiently with binding affinity of -8.4, -8.9, -7.7, -6.6 and -6.8 Kcal/mol against AChE enzyme, BuChE enzyme, BACE-1 enzyme, Aβ monomer and Aβ protofibril, respectively as a result it can be carried forward for the further preclinical and clinical studies.

Introduction

Alzheimer’s Disease (AD) is one of the most prevalent neurodegenerative disease affecting mostly the aged above 60 years of age marked by cognitive decline. Accumulating evidence suggests that presence of both environmental factors and genetic factors are responsible for various pathophysiological pathways of AD. Deposition of extracellular amyloid plaques and intracellular hyperphosphorylated, characterize the neuropathological hallmarks of AD. Environmental factors include chronic accumulation of aluminium in brain due drinking water and genetic factors comprised mutation of APP gene and Presenilins leading to accumulation of neurotoxic amyloid-β (Aβ) in the brain.

There is a plethora of phytochemicals available which has it’s own therapeutic property in it’s own right. Various phytochemicals have been known to show potential activity against AD, flavonoids and alkaloids are amongst the most important ones to make a mention about [1]. Since time immemorial, alkaloids have been known to be beneficial in therapeutics. Alkaloids are nitrogen containing heterocycles; galantamine and rivastigmine (a synthetic analogue of physostigmine) being USFDA approved for AD [2].

Computational studies incorporated in phytochemical screening have been beneficial for determining various phytochemicals. Traditional approach towards phytochemical research has evolved with fusion of computational approach. In this study, we selected few phytochemicals and did computational studies against the prominent targets known as hallmark proteins responsible for the pathophysiological conditions of the AD patients. Fifteen phytochemicals, majority of then broadly falls in the alkaloidal group and few comprised of flavonoids and terpenoids. We did a multitarget docking study to find out the potential targets against which the chemicals showed binding affinity. We selected a acetylcholinesterase protein the principle protein which caused cholinergic crisis in AD affected brains, a butyrlcholinesterase protein which is also responsible for the cholinergic etiology. A BACE or β-secretase is an enzyme which is very crucial protein for formation of neurotoxic Aβ plaques. We have also included Aβ monomer and oligomer in this computational study as proteins against the phytochemicals of our interest.

Results and Discussion

Rationale of Selection of Phytochemicals

The current AD treatment functions to alleviate mental, behavioural and cognitive symptoms. The existing treatments relay on Donepazil, Galantamine, Rivastigmine and Tacrine that are Acetylcholinesterase Inhibitors (AChEI’s) and Memantine that blocks N-Methyl-D-Aspartate (NMDA) receptors (Figure 1). Further some antidepressants and antipsychotic treatment can be employed to improve the behavioural symptoms.